Evidence map›Paper›PMID 39976252›Full record

ArticleJournal of clinical and experimental neuropsychology

Usability of the Mayo Test Drive remote self-administered web-based cognitive screening battery in adults aged 35-100 with and without cognitive impairment.

Jay S Patel, Teresa J Christianson, Logan T Monahan, Ryan D Frank, Winnie Z Fan, John L Stricker, Walter K Kremers, Aimee J Karstens, Mary M Machulda, Julie A Fields and 6 more

Abstract read
In one paragraph

Article in Journal of clinical and experimental neuropsychology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jay S PatelDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Teresa J ChristiansonDivision of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Logan T MonahanDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Ryan D FrankDivision of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Winnie Z FanDivision of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
John L StrickerDepartment of Information Technology, Mayo Clinic, Rochester, MN, USA.
Walter K KremersDivision of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Aimee J KarstensDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Julie A FieldsDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Jason HassenstabDepartment of Neurology and Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, MO, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Nikki H StrickerDivision of Neurocognitive Disorders, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9034-1252

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validation of the Mayo Test Drive Screening Battery Composite and Stricker Learning Span for Early Detection and Monitoring of Cognitive Decline in Preclinical and Prodromal Alzheimer’s DiseaseR01AG081955 · NIA · MAYO CLINIC ROCHESTER · PI Nikki H Stricker · 2024 to 2026
$4.4M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
Stricker Learning Span: A Computer Adaptive Word List Memory Test Optimized for Remote AssessmentR21AG073967 · NIA · MAYO CLINIC ROCHESTER · PI STRICKER, NIKKI H · 2021 to 2021
$437k
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG081955NIA NIH HHS R21 AG073967NIA NIH HHS R37 AG011378NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

backgroundMayo Test Drive (MTD): Mayo Test Development through Rapid Iteration, Validation and Expansion, is a web-based remote cognitive assessment platform for self-administered neuropsychological measures with previously demonstrated validity and reliability. We examined the usability of MTD and hypothesized that completion rates would be greater than 90%. We explored whether completion and participation rates differed by cognitive status and demographic factors.

methodsA total of 1,950 Mayo Clinic Study of Aging and Mayo Alzheimer's Disease Research Center participants (97% White, 99% Non-Hispanic) were invited to participate in this ancillary, uncompensated remote study. Most invitees were cognitively unimpaired (CU;

resultsBaseline session completion rates were 98.5% (

conclusionsMTD demonstrated high usability as defined by completion rates in this research sample that includes a broad age range, though participation rates are lower in individuals with cognitive impairment. Results support good adherence at follow-up, feasibility through mean session duration, and acceptability based on qualitative analysis of participant comments.

Indexed as

Cognitive DysfunctionInternetNeuropsychological TestsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedReproducibility of Resultsagingcomputerized neuropsychological assessmentDigital healthfeasibilityneuropsychologysmartphone

Identifiers

PMID39976252
PMCPMC12129114

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.